StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.85−0.15 (-5.15%)

Close on Nov 18, 2026Market cap $304.54MP/E –Yield –

Relmada Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Relmada Therapeutics

Relmada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Relmada Therapeutics figures

See a number that looks wrong?